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Abbreviations
Chemical receptors and substance
TRPV1: transient receptor potential vanilloid-1
CGRP: calcitonin gene-related peptide
Medications and agents
DKT: daikenchuto
BCTC: N-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide
Others
S.E.M.: standard error of mean
ANOVA: analysis of variance
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Introductory Remarks
Transient receptor potential channels
Transient receptor potential (TRP) channels are nonselective calcium ion channels ubiquitously 
expressed in many tissues and respond to a broad range of physical, chemical, and environmental 
stimuli such as taste, temperature, change in osmolarity, pressure, stretch, and light.  TRP channels 
are divided into seven subfamilies, and different types of TRP channels are present in humans.  
Natural products, especially medicinal and culinary herbs such as chili pepper, mustard oil, and 
menthol, stimulate some of these TRP channels.  In recent years, elucidation of the role of TRP 
channels in gastrointestinal physiology, including intestinal motility, secretion, and visceral 
sensation, has attracted a lot of attention [1,2,3,4].  However, the physiological implications of TRP 
channels in gastrointestinal blood flow remain to be completely elucidated.
Capsaicin, a selective transient receptor potential vanilloid-1 agonist, in chili pepper
Transient receptor potential vanilloid-1 (TRPV1) was discovered as a thermosensor, which reacts to 
temperatures greater than 43°C.  TRPV1 senses spicy tastes in free sensory nerve terminals, is 
activated by acids and pungent substances like capsaicin, and is involved in inflammatory thermal 
hyperalgesia.  Sensory nerve fibers expressing TRPV1 are polymodal nociceptors that are also 
sensitive to chemical irritants such as gastric acid and noxious heat [5] and a mechanical target for 
pain [6].  Red hot chili peppers are a species of the genus Capsicum, and they have been used in 
foods as a spice for their pungency since 7000 B.C.  In folk medicine, capsicum extract is used for 
appetite stimulation, relief for toothache, treatment for gastric ulcers, and rheumatism [5].  
Capsaicin, a pungent ingredient of the chili pepper, is the most typical selective TRPV1 agonist.  
Capsaicin exerts a gastroprotective effect against experimental gastric injury induced by activation 
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of TRPV1 [7].  However, some studies show that capsaicin alleviates gastrointestinal disease, and 
that this effect is associated with the activation of TRPV1.
Kampo formula for gastrointestinal disorders
Traditional Japanese medicines, including Kampo medicines have been used for 1500 years [8].  
Traditional Kampo medicine has been practiced widely and has been integrated into Western 
medicine in Japan.  Kampo formulas are prescribed for various gastrointestinal disorders.  These 
formulas are intended not only to restore homeostasis in the human body [8], but also to treat 
disorders, especially indigestion.  In addition, some textbooks on Oriental medicine state that some 
formulas have clinical effects on problems of the upper gastrointestinal tract, such as epigastralgia 
and abdominal distress. 
 
Daikenchuto and gastrointestinal disorders
Daikenchuto (DKT) is one of the most frequently prescribed Kampo formulas in Japan, and it 
consists of the following four crude drugs: processed ginger, ginseng, zanthoxylum fruit, and malt 
sugar in the ratio of 5:3:2:80.  DKT is used for the treatment of a cold sensation in the abdomen and 
intestinal disorders of motility and inflammation such as postoperative bowel ileus [8].  
Additionally, textbooks on Oriental medicine indicate that DKT has been used not only for 
intestinal disorders but also for problems of the upper gastrointestinal tract such as epigastric pain 
and bloating.  Further, DKT ameliorates the delayed gastric motility induced by morphine and 
chlorpromazine in mice [9,10].
A previous study showed that DKT increases blood flow in the small intestine of rats [11].
However, the effect of DKT on gastric mucosal blood flow has not been investigated thus far.
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Involvement of nitric oxide synthase isoforms in increased gastric mucosal blood flow by 
capsaicin
We have reported that capsaicin stimulates the primary afferent nerves through activation of 
TRPV1, which results in gastric mucosal protection [12] and gastric hyperemic response [13], 
which are mediated by calcitonin gene-related peptide (CGRP) and nitric oxide (NO) [14,15].  
Vasodilation of the gastric mucosa induced by intragastric application of capsaicin decreased after 
treatment with an inhibitor of NO synthase (NOS), NG-nitro-L-arginine methyl ester (L-NAME) 
[16].  NO affects gastric mucosal blood flow (GMBF) [17].  In mammals, three isoforms of NOS 
encoded by different genes have been identified [18].  Neuronal NOS (nNOS) and the isoform 
present in the endothelium lining the vasculature, endothelial NOS (eNOS), are constitutively 
expressed in humans.  Inducible NOS (iNOS) requires a stimulus (cytokines and 0
lipopolysaccharides) for expression in specific cell types such as macrophages, neutrophils, and 
epithelial cells.  Therefore, eNOS-derived NO is assumed to contribute to the gastric hyperemic 
response to capsaicin although the gastric mucosa has been shown to contain not only eNOS 
[19,20] but also nNOS [19] and iNOS [21].  Interestingly, Chen et al. [22] speculated that NO is 
produced not only from the endothelium but also from nitroxidergic nerves in the submucosa in 
gastric vasodilation response to capsaicin.  However, which isoform of NOS contributes to gastric 
hyperemic responses to capsaicin has not been determined thus far.
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Aim and Scope
The aim of this study was to clarify whether the TRPV1 agonist capsaicin and the relevant Kampo 
formula DKT increases gastric mucosal blood flow through activation of TRPV1 and nNOS.
The specific aims of the proposal studies were:
Part 1 Capsaicin
(1) To clarify the roles of NOS isoforms on the gastric hyperemic response to capsaicin in 
urethane-anesthetized rats by using pharmacological tools, including N5-[imino 
(propylamino) methyl]-L-ornithine (L-NPLA; a selective nNOS inhibitor), N5-(l-iminoethyl)-
L-ornithine (L-NIO; a selective eNOS inhibitor), and 1400W (a selective iNOS inhibitor).
(2) To verify the interaction of nNOS and TRPV1-expressing nerves in the stomach of rats by 
using immunohistochemical analysis.
Part 2 Kampo formulas
(1) To clarify whether DKT increases gastric mucosal blood flow through activation of TRPV1 
in rats.
(2) To verify whether nNOS-derived NO is involved in the gastric mucosal hyperemic response 
to DKT in rats.
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Ethics
Animal experiments were performed in compliance with the “Guiding Principles for the Care and 
Use of Laboratory Animals” approved by the Japanese Pharmacological Society and the guidelines 
approved by the Ethical Committee on Animal Care and Animal Experimentation of Josai 
International University (#52).  The number of animals used was kept to the minimum necessary for 
meaningful interpretation of the data.
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Part 1 Effects of the TRPV1 agonist capsaicin on gastric mucosal blood flow in the stomach of 
anesthetized rats ex vivo
Introduction
Capsaicin-sensitive afferent nerves play an important role in maintaining the integrity of the gastric 
mucosa.  Stimulation of these nerves by capsaicin protects the gastric mucosa from a variety of 
noxious stimuli through increased gastric mucosal blood flow (GMBF) [23,24].  The binding site of 
capsaicin has been cloned and is known as the transient receptor potential vanilloid-1 (TRPV-1), a 
nonselective cationic channel [25].  Previously, we reported that capsaicin stimulates these afferent 
nerves through activation of TRPV1, which results in gastric mucosal protection [12] and gastric 
hyperemic response [13], which are mediated by calcitonin gene-related peptide (CGRP) and nitric 
oxide (NO) [14,15].  NO affects GMBF [17]. 
In mammals, three isoforms of NOS encoded by different genes have been identified [18].  The 
constitutively expressed isoforms include neuronal NOS (nNOS) and endothelial NOS (eNOS) 
present in the endothelium lining the vasculature.  Inducible NOS (iNOS) requires a stimulus 
(cytokines and lipopolysaccharides) for expression in specific cell types such as macrophages, 
neutrophils, and epithelial cells.  Therefore, eNOS-derived NO is assumed to contribute to the 
gastric hyperemic response to capsaicin although the gastric mucosa has been shown to contain not 
only eNOS [19,20] but also nNOS [19] and iNOS [21].  However, which isoform of NOS 
contributes to gastric hyperemic responses to capsaicin has not been determined thus far.
In the present study, we examined the roles of NOS isoforms on the gastric hyperemic response to 
capsaicin in urethane-anesthetized rats by using pharmacological tools, including N5-[imino 
(propylamino) methyl]- L-ornithine (NPLA; a selective nNOS inhibitor), N5-(l-iminoethyl)-L-
ornithine (L-NIO; a selective eNOS inhibitor), and 1400W (a selective iNOS inhibitor).  In addition, 
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we investigated the interaction of nNOS and TRPV1-expressing nerves in the stomach of rats by 
using immunohistochemical analysis.
Material and Methods
Animals
Male Sprague–Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180–220 g were used.  
Animals were housed under controlled environmental conditions (temperature, 24 ± 2°C and lights 
on 7:00 AM to 7:00 PM) and fed commercial rat chow MF (Oriental Yeast, Tokyo, Japan).  The 
animals were kept in individual cages with raised mesh bottoms to prevent coprophagy, and they 
were deprived of food but allowed free access to tap water for 18 h before the experiments.  Animal 
experiments were performed according to the “Guiding Principles for the Care and Use of 
Laboratory Animals” approved by the Japanese Pharmacological Society and the guidelines 
approved by the Ethical Committee on Animal Care and Animal Experimentation of Josai 
International University (#52).  The number of animals used was kept to the minimum necessary for 
meaningful interpretation of the data.
Experimental procedures
Chemical deafferentation was performed two weeks before the experiment by successive 
subcutaneous injections of capsaicin once daily for 3 days (20, 30, and 50 mg/kg) [26].  All 
capsaicin injections were performed under ether anesthesia, and the rats were pretreated with the 
beta-adrenergic receptor agonist isoproterenol (0.01 mg/kg, intramuscular [i.m.]) and the selective 
beta 1-adrenergic antagonist atenolol (0.01 mg/kg, i.m.) to counteract the respiratory impairment 
associated with capsaicin injection.  To verify the effectiveness of the treatment, a drop of a 0.1 mg/
mL solution of capsaicin in 0.5% carboxymethyl cellulose solution (CMC) was instilled into one 
10
eye of each rat, and the protective wiping movements were counted [27].  The animals were 
anesthetized with urethane (1.25 g/kg, intraperitoneal [i.p.]) and pretreated with omeprazole (60 
mg/kg, i.p.) to exclude the possibility that activation of TRPV1 by H+ facilitates the increased 
GMBF responses [28].  The stomach was exposed through a midline incision, delivered onto the 
abdominal surface by gentle traction on the spleen, and the pylorus was ligated.  A two-part lucite 
chamber was used for maintaining ex vivo conditions of the gastric mucosa.  One part is a lucite 
base, and the other is a plastic rim, which has two holes on the side wall.  The two holes are 
cannulated for perfusing the mucosa with saline (154 mmol/L NaCl, 37°C) at a flow rate of 1 mL/
min.  The lucite base was lowered over the animal, and the stomach was drawn through the center 
hole with the forceps applied only to the forestomach.  The stomach was then opened along the 
greater curvature from the middle part of the forestomach to the area where the epiploic artery 
terminates, and the edges were expanded by gently stretching the glandular mucosa.  The plastic 
rim was then applied and pressed down on the mucosa.  Under these conditions, only the area of the 
glandular mucosa, which consists mostly of the corpus region, was exposed.  The chamber was set 
at the level of the abdominal wall so that the external wall of the stomach remained inside the 
abdominal cavity.  The body temperature was maintained at a temperature similar to that of the 
rectum at around 37°C by using a small animal warmer and thermometer (Model BWT-100; Bio 
Research Center, Nagoya, Japan) [29].  GMBF was measured using laser-Doppler flowmetry 
(Model ALF-21N; Advance, Tokyo, Japan) and a non-touching probe (diameter, 1 mm) on the 
surface of the corpus mucosa.  Arterial pressure (AP) was monitored via the femoral artery by using 
a blood pressure transducer (DX-100; Nihon Kohden, Tokyo, Japan) and amplifier system (Nihon 
Kohden AP-601G & AP-611).  After GMBF and AP were well stabilized, the perfusion was 
discontinued, the luminal solution was removed, and the mucosa was exposed to 2 mL of capsaicin 
(0.33–3.3 mmol/L) for 10 min.  After application of capsaicin, the mucosa was rinsed with saline, 
another 2 mL of saline was instilled, and the perfusion was resumed.  Changes in the GMBF were 
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continuously monitored and recorded for 2-h test periods by using a PowerLab system (Model 
ML845; AD Instruments, Bella Vista, NSW, Australia).  A TRPV1 antagonist N-(4-t-
butylphenyl)-4-(3-chlopyridin-2-yl) tetrahydropyrazine-1(2H)-carboxamide (BCTC) (0.8 mmol/L, 
i.g.) [30,31], a nonselective NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 5 and 10 
mg/kg, i.v.), a nNOS selective inhibitor NPLA (0.02 and 0.2 mg/kg, i.v.), an eNOS selective 
inhibitor L-NIO (3 and 10 mg/kg, i.v.), or an iNOS selective inhibitor 1400W (3 and 10 mg/kg, i.v.) 
were administered 20 min before exposing the stomach to 2 mL of capsaicin for 10 min.  In one 
group, L-arginine (300 mg/kg, i.v.) was administered twice 40 min and 60 min before the 
application of capsaicin.
Preparations and drugs used
Allyl isothiocyanate, atenolol, capsaicin, CMC, dimethyl sulfoxide (DMSO), dl-isoproterenol, and 
urethane (ethyl carbamate) were obtained from Wako Pure Chemical Industries (Osaka, Japan).  
Carbamyl-β-methylcholine chloride (bethanechol chloride), L-arginine, L-NAME, and omeprazole 
were from Sigma-Aldrich (St. Louis, MO, USA).  NPLA and L-NIO were purchased from Tocris 
Cookson (Ellisville, MO, USA).  BCTC was purchased from BIOMOL (Plymouth Meeting, PA, 
USA).  Capsaicin was dissolved in Tween 80-ethanol solution (10% ethanol, 10% Tween 80, and 
80% saline) [26] for subcutaneous (s.c.) injection or suspended in 0.5% CMC for mucosal 
application.  Indomethacin was suspended in 1% Tween 80 in saline for s.c. injection.  Omeprazole 
was suspended in 0.5% CMC for i.p. injection.  BCTC was dissolved in DMSO before in saline, 
and the final concentration of DMSO was less than 1.0%.  Other drugs were dissolved in saline with 
no organic solvent or detergent.  Each drug was prepared immediately before use and was 
administered at a volume of 0.5 mL/100 g of body weight for i.p. and s.c. administration or at a 
volume of 0.1 mL/100 g of body weight for intravenous (i.v.) administration.  Control animals 
received the vehicle alone.
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Statistics
The data are presented as the mean ± standard error of mean (S.E.M.) of 3 to 7 rats per group.  The 
statistical significance of differences between two groups was assessed using Student’s t-test.  
Multiple comparisons against a single control group were made using one-way analysis of variance 
(ANOVA) with Bonferroni correction.  The level of significance was set at 0.05.  Sigma Stat 3.1 
software (Jandel Scientific Software, San Rafael, CA, USA) was used for statistical analysis.
Results
Effects of intragastric capsaicin on GMBF in the stomach of anesthetized rats ex vivo
Intragastric administration of capsaicin (0.33, 1, and 3.3 mmol/L) induced gastric hyperemic 
responses in a concentration-dependent manner; a significant effect was observed at concentrations 
greater than 1 mmol/L (Fig. 1B).  The GMBF after intragastric application of 0.33, 1, and 3.3 mmol/
L of capsaicin for 10 min was 121.5 ± 2.6%, 146.4 ± 8.9%, and 178.6 ± 12.9%, respectively.  
Interestingly, the GMBF in response to 3.3 mmol/L capsaicin remained significantly high despite 
the removal of capsaicin from the chamber (data not shown).  Mucosal application of the control 
solution (0.5% CMC) did not increase the GMBF (Fig. 1A).  GMBF reached the maximal value 
after treatment with 3.3 mmol/L of capsaicin; therefore, this concentration was used in the 
subsequent experiments to examine the effects of various agents on the GMBF in response to 
capsaicin.  The increased GMBF in animals in response to capsaicin (3.3 mmol/L) was totally 
abolished when the gastric mucosa was exposed to a TRPV1 antagonist BCTC (0.8 mmol/L; Fig. 
2A, B).  The maximum GMBF induced by 3.3 mmol/L capsaicin in the presence of BCTC was 
102.4 ± 6.1% throughout the experiment.  A similar phenomenon was observed in the animals after 
chemical deafferentation by consecutive injections of capsaicin (total 100 mg/kg, s.c.) two weeks 
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before the experiment (Fig. 2A, B).  In these animals, the GMBF remained unchanged during 
exposure of the mucosa to capsaicin (3.3 mmol/L), and the maximum GMBF was 103.1 ± 4.2%.  
However, intragastric capsaicin significantly increased the GMBF via activation of TRPV1 
expressed in capsaicin-sensitive sensory nerves without deafferentation in anesthetized rats.
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Fig. 2 Effects of N-(4-t-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide 
(BCTC), a transient receptor potential vanilloid-1 (TRPV1) antagonist, and sensory deafferentation on 
gastric mucosal blood flow (GMBF) induced by mucosal application of capsaicin to the stomach of 
anesthetized rats ex vivo.  Chemical deafferentation (capsaicin pretreatment) was performed 2 weeks 
before the experiment by consecutive subcutaneous (s.c.) injections of capsaicin once daily for 3 days 
(total dose, 100 mg/kg).  Figure A shows the time course of GMBF response to capsaicin (3.3 mmol/L) 
in anesthetized rats treated with BCTC or sensory deafferentation.  The stomach was perfused with 
saline, BCTC (0.8 mmol/L) was applied to the chamber for 30 min, starting at 20 min before the 
capsaicin application.  Capsaicin was topically applied to the mucosa for 10 min.  The data are 
expressed as a % increase in baseline values and represent the mean ± standard error of mean (S.E.M.) 
of values obtained every 2 or 10 min from 3 to 4 rats.  Statistically significant difference at P < 0.05: 
*from the corresponding values in the group treated with vehicle.  Figure B shows a maximal GMBF 
response induced by mucosal application of capsaicin (3.3 mmol/L).  The data are expressed as a % 
increase of baseline values and represent the mean ± S.E.M. of 3–4 rats.  * indicates statistically 
significant difference at P < 0.05 compared to the group treated with vehicle.  Note that increased 
GMBF in response to capsaicin was completely abolished by BCTC and sensory deafferentation.
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Effects of L-NAME, a non-selective NOS inhibitor, and combination treatment with L-NAME 0
and L-arginine (300 mg/kg, ×2) on GMBF in response to capsaicin in the stomach of 
anesthetized rats ex vivo
GMBF temporarily increased after injection of L-NAME but immediately returned to the baseline 
value (Fig. 3A).  The baseline value of arterial pressure (AP) in urethane-anesthetized rats was 
about 50–100 mmHg, and the AP did not change after intravenous injection of the vehicle (saline) 
20 min before mucosal application of capsaicin (Fig. 4A).  However, the AP increased immediately 
from about 75–100 mmHg to about 120–150 mmHg after the administration of L-NAME (10 mg/
kg, iv), and the increase in AP induced by L-NAME was retained throughout the experiment (Fig. 
4B).  The increase in GMBF in response to capsaicin (3.3 mmol/L) observed in control rats was 
apparently decreased by L-NAME in a dose-dependent manner.  The maximum GMBF in response 
to capsaicin in animals treated with L-NAME (5 and 10 mg/kg) was 138.8 ± 11.6% and 125.6 ± 
11.6% (Fig. 3B). 
In contrast, the substrate for NOS L-arginine (300 mg/kg), which was pretreated twice, reversed the 00 0 0
inhibitory effects of L-NAME (10 mg/kg) on gastric hyperemic response during capsaicin 
application (Fig. 3A, B).  Thus, gastric hyperemia in response to capsaicin was attributable to both 
NO-dependent and NO-independent hyperemia during capsaicin application in anesthetized rats.
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Fig. 4.  Representative effects of NG-nitro-L-arginine methyl ester (L-NAME) on gastric mucosal blood 0
flow (GMBF) and arterial pressure (AP) in urethane-anesthetized rats.  Vehicle (saline; A) and L-NAME 
(10 mg/kg; B) were intravenously injected 20 min before capsaicin application.  The AP and GMBF 
increased immediately after the administration of L-NAME (10 mg/kg) unlike that in the vehicle group; 
subsequently, AP, but not GMBF, remained at high levels throughout the experiment.
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Effect of NPLA, a selective nNOS inhibitor, on GMBF in response to capsaicin in the stomach 0
of anesthetized rats ex vivo
The roles of different isoforms of NOS in the gastric hyperemia induced by capsaicin were 
investigated by using selective NOS inhibitors, including the nNOS inhibitor NPLA, the eNOS 
inhibitor L-NIO, and the iNOS inhibitor 1400W.  Administration of the nNOS specific inhibitor 
NPLA alone did not significantly affect the GMBF (Fig. 5A).  Interestingly, the increase in GMBF 
in response to capsaicin (3.3 mmol/L) during the application was apparently decreased by 
administration of 0.2 mg/kg NPLA.  The maximum GMBF during capsaicin application in animals 
treated with NPLA (0.02 and 0.2 mg/kg) were 182.1 ± 26.6% and 141.9 ± 8.9% (Fig.5B).  
Preliminary experiments showed that AP in rats treated with NPLA (2 mg/kg, iv) returned to the 
baseline value, which was about 55–80 mmHg although the AP increased temporarily after the 
administration of NPLA (Fig. 6A).
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Fig. 6 Representative effects of N5-[imino (propylamino) methyl]-L-ornithine (NPLA), and N5-(l-0
iminoethyl)-L-ornithine (L-NIO) on gastric mucosal blood flow (GMBF) and arterial pressure (AP) in 
urethane-anesthetized rats.  NPLA (2 mg/kg; A) and L-NIO (10 mg/kg; B) were intravenously injected 
20 min before capsaicin application.  AP in the NPLA-treated rats (2 mg/kg) returned to the baseline, 
while AP, but not GMBF, increased temporarily after the administration of NPLA.  AP in rats treated 
with L-NIO (10 mg/kg) was maintained at a level slightly above the baseline although AP and GMBF 
transiently increased after the administration of L-NIO.
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Effect of L-NIO, a selective eNOS inhibitor, on GMBF in response to capsaicin in the stomach 0
of anesthetized rats ex vivo
Administration of the selective eNOS inhibitor L-NIO (10 mg/kg) alone temporarily increased the 
GMBF, but the GMBF immediately returned to the baseline value (Fig. 7A).  The gastric hyperemic 
response after treatment with capsaicin was not significantly affected by L-NIO (3 and 10 mg/kg), 
and the maximum GMBF was 158.7 ± 8.4% and 160.0 ± 9.6% (Fig. 7B).  Preliminary experiments 
showed that the AP in rats treated with L-NIO (10 mg/kg, iv) was maintained at a slightly higher 
level than that at the baseline, which was about 50–60 mmHg to about 65–75 mmHg (Fig. 6B) 
although the AP transiently increased after the administration of L-NIO.
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Effect of 1400W, a selective iNOS inhibitor, on GMBF in response to capsaicin in the stomach 0
of anesthetized rats ex vivo
GMBF was unchanged by the administration of the iNOS selective inhibitor 1400W (10 mg/kg) 
(Fig. 8A).  In addition, the increased GMBF in response to capsaicin was not affected by 1400W (3 
and 10 mg/kg, Fig. 8B). 
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Fig. 8 Effect of 1400W, a selective inducible nitric oxide synthase (iNOS) inhibitor, on gastric mucosal 
blood flow (GMBF) induced by capsaicin in the stomach of anesthetized rats ex vivo.  Figure A shows 
the time course of analysis for the effect of 1400W (10 mg/kg) on GMBF response to capsaicin (3.3 
mmol/L) in anesthetized rats.  The stomach was perfused with saline before the application, 1400W (3 
and 10 mg/kg) was administered via an intravenous injection 20 min before capsaicin application, and 
capsaicin (3.3 mmol/L) was topically applied to the mucosa for 10 min.  The data are expressed as a % 
increase in baseline values and represent the mean ± standard error (S.E.) of values every 2 or 10 min 
from 4 rats.  Figure B shows the maximum GMBF during capsaicin (3.3 mmol/L) application in animals 
treated with 1400W (3 and 10 mg/kg).  The data are expressed as a % increase of baseline values and 
represent the mean ± S.E. of 4–5 rats.  Note that the increased GMBF in response to capsaicin was not 
affected by 1400W.
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Distribution of TRPV1 immunoreactivity in the rat stomach 0
Numerous TRPV1-immunoreactive axons were found around in arterioles in the mucosal and 
submucosal layer of the stomach (Fig. 9A, D).  In addition, many TRPV1 axons were observed to 
be immunoreactive for nNOS (Fig. 9C, F).  A few axons of this type were present in the mucosa 
(Fig. 9C), but they were particularly abundant in the vicinity of blood vessels in the submucosa 
(Fig. 9F).
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Discussion
In this chapter, we found that intragastric application of capsaicin facilitates an initial increase in 
GMBF by NO mainly derived from nNOS after stimulating capsaicin-sensitive sensory nerves, and 
that the sustained hyperemic response ?after removal of capsaicin might be attributed to eNOS/NO 0
in the rat stomach.  In addition, capsaicin-sensitive sensory nerves are involved in maintenance of 
the gastric mucosal integrity against irritants [14,23,28].  Topical application of capsaicin causes 
dilatation of the submucosal and mucosal arterioles in the rat stomach [32,33].  Our findings were 
consistent with those reported previously in that mucosal application of capsaicin increased GMBF 
in the rat stomach, and this effect was totally abolished by a TRPV1 antagonist, BCTC, and 
chemical deafferentation by capsaicin pretreatment, which suggested that this action is mediated by 
capsaicin-sensitive sensory nerves expressing TRPV1.  In addition, the GMBF responses to 
capsaicin were markedly inhibited by a non-selective NOS inhibitor L-NAME, which indicated that 
mainly NO is involved in those hyperemic responses.  However, L-NAME did not inhibit the 
increases in GMBF as much as BCTC.  This result suggests that gastric mucosal hyperemia in 
response to capsaicin is attributable not only to NO but also to other mediators, including 
prostaglandins (PGs) and CGRP.  Several studies have shown that endogenous prostaglandins 
(PGs), especially PGI2, contributes to gastric hyperemic responses to capsaicin by sensitizing 
TRPV1-expressing afferent nerves, which was revealed by the treatment of indomethacin (5 mg/kg, 
s.c.) and the animals lacking IP receptors [24,34,35].  In addition, Chen et al. reported the 
interaction of NO and CGRP in gastric vasodilation through sensory nerves [22].  These results can 
be explained by the previous findings that BCTC functionally antagonizes the action of capsaicin at 
the peripheral terminals of sensory nerves and inhibits the release of some transmitters from 
capsaicin-sensitive afferent nerves [30,31].  Further, Chen et al. reported that submucosal 
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application of CGRP induced dose-dependent dilation of gastric submucosal arterioles, which was 
significantly decreased by L-NAME [33].  However, the dilation induced by submucosal CGRP was 
decreased to a much lesser degree by inhibition of NO synthesis than that induced with intragastric 
capsaicin.  This indicates that the NO released by CGRP was not the only source of submucosal NO 
in capsaicin-induced dilation, and that there may be another source of submucosal NO such as 
nitroxidergic nerves that has not been determined thus far [22].  NO is synthesized from L-arginine 
by NOS in various cells.  NOS is present not only in vascular endothelial cells (eNOS) but also in 
perivascular nerves (nNOS) [18,34].  It is well known that NO is a vasodilator that increases 
GMBF, and this mediator is important in the modulation of gastric mucosal integrity through 
interaction with sensory nerves [14].  The increase in GMBF in response to capsaicin is mitigated 
by NG-monomethyl L-arginine, and the gastric cytoprotection induced by capsaicin is also 
decreased by the NOS inhibitor [32,33].  Previous studies have shown that gastric hyperemia 
caused by acid back-diffusion or exogenous CGRP is mediated partly by NO, but which NOS 
isoform is involved in those hyperemic responses has not been investigated in any of the studies 
thus far.  In addition, the source of the NO involved in the actions of capsaicin was not identified 
[14].  That is because highly selective inhibitors of NOS isoforms had not been developed at that 
time.  We investigated which NOS isoform mediates the increased GMBF in response to capsaicin.  
In this study, NPLA and L-NIO were adopted as selective nNOS and eNOS inhibitors, respectively.
NPLA rapidly binds to nNOS and is slowly dissociated from nNOS in vitro followed by inhibition 
of NO production [36], and NPLA exerts potent inhibition of nNOS with an observed IC50 value of 
57 nM, a value149-fold and 3,158-fold lower than the concentration of NPLA required to inhibit the 
eNOS and iNOS isoforms, respectively [38,39].  However, an in vivo pharmacokinetic analysis of 
the half-life of NPLA has not been performed thus far.  However, recent studies showed that 
administration of NPLA at a dose of 0.5–2 mg/kg (i.p.) for 90 min and 2 µg/kg (i.c.v) for 120 min to 
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different animal models showed a persistent inhibition of nNOS [38,39].  These findings are 
consistent with our results that NPLA inhibits nNOS activity throughout the experiment. 
In addition, L-NIO was the most potent inhibitor of the eNOS isoform; the IC50 value of L-NIO 
was 0.08 µM, which was approximately 4-fold lower than that observed for iNOS (IC50 = 0.3 µM) 
and nNOS (IC50 = 0.3 µM) isoforms [40].  However, the selectivity of L-NIO is not very high, and 
this agent at a high dose (>30 mg/kg) also suppresses the iNOS isoform [20,41].  Further, L-NIO 
inhibits eNOS activity in vivo for 4 h [20]. 
NPLA significantly decreased the maximal GMBF response during the application of capsaicin.  In 
contrast, L-NIO did not affect the maximal GMBF response induced by capsaicin.  These results 
suggest that nNOS/NO, which might be released from TRPV1-expressing nerves stimulated by 
capsaicin, plays an important role in gastric hyperemia during the luminal application of capsaicin.  
On the other hand, intravenous injection of 1400W did not affect the resting GMBF or the increase 
in GMBF in response to capsaicin.  Our results were consistent with those reported previously that 
eNOS was expressed mostly in the vasculature throughout the gastric mucosa in rats, but the 
expression of iNOS was hardly observed in the gastric mucosa of normal rats by using 
immunohistochemical analysis [19,20].  These findings support our hypothesis that eNOS/NO plays 
a role in the resting state responses of GMBF, while iNOS/NO plays no role in the increased GMBF 
in response to capsaicin. 
In this study, TRPV1 immunoreactivity was detected in the mucosal and submucosal layers of the 
corpus of the rat stomach.  Many TRPV1 nerve fibers contain nNOS, but not all axons do.  In 
addition, numerous TRPV1-immunoreactive axons were found around arterioles in the submucosal 
layer.  These data led us to speculate that the capsaicin-induced increase in GMBF could be 
attributed to nNOS/NO in that capsaicin stimulates TRPV1 nerves and releases CGRP and NO, and 
NO is immediately provided by nNOS and dilates the blood vessels.  Stimulation of sensory nerves 
leads to gastric hyperemic response, which is mediated partly by NO formation, but it is not clear 
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whether the NO is derived solely from endothelial cells or is also released directly by extrinsic and/
or intrinsic nerves [14,22].  To our knowledge, this is the first study in which abundant TRPV1 
axons containing nNOS in the submucosa with a high density of immunoreactive axons around 
blood vessels have been reported.  Therefore, our study suggests that capsaicin and/or nerve 
activation is likely to cause vasodilatation by inducing NO release from TRPV1-expressing 
extrinsic sensory fibers.  In the corpus, TRPV1/nNOS immunoreactive axons were also present in 
the mucosa.
Summary
In conclusion, our results showed that mucosal application of capsaicin increased GMBF by 
releasing NO derived from nNOS after stimulation of capsaicin-sensitive sensory nerves.  To our 
knowledge, this is the first study in which the contribution of nNOS-derived NO in gastric 
hyperemic responses to the activation of TRPV1 by capsaicin has been reported using not only 
pharmacological but also immunohistological techniques.
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Part 2 Effects of Daikenchuto on gastric mucosal blood flow in rats
Introduction
Kampo formulas are prescribed for various gastrointestinal disorders [8].  Daikenchuto (DKT), 
which is used for the treatment of a cold sensation in the abdomen (mainly umbilical portions) and 
decreasing intestinal dysmotility and inflammation, is one of the most frequently prescribed kampo 
formulas in Japan.  DKT consists of four crude drugs as follows: processed ginger, ginseng, 
zanthoxylum fruit, and malt sugar.  DKT increases the intestinal blood flow in rats and improves the 
small intestinal movement in guinea pigs [11, 43], and a previous study has shown that DKT 
increases the levels of gastrointestinal hormones and neuropeptides such as motilin, vasoactive 
intestinal peptide (VIP), and calcitonin gene-related peptide (CGRP) [8].  In addition, Kono et al. 
reported that DKT induces an increase in mucosal blood flow in rat colon via CGRP but not via 
VIP and nitric oxide (NO) [44].  These results support the finding that the increase in blood flow in 
the gastrointestinal tract lead to the clinical effect of DKT against the cold feeling and dysmotility 
in the abdomen.  However, the mechanism underlying the increase in the gastric mucosal blood 
flow induced by DKT remains to be clarified.  The aim of this study was to determine whether 
DKT facilitates an increase in the mucosal blood flow in the stomach of rats through activation of 
transient receptor potential vanilloid-1(TRPV1), which is expressed in nerve fibers containing the 
vasodilator CGRP and NO.
Material and Methods
Animals
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Male Sprague–Dawley strain rats (SLC, Hamamatsu, Japan) weighing 180–220 g were used.  
Animals were housed under controlled environmental conditions (temperature, 24 ± 2°C and lights 
on 7:00 AM to 7:00 PM) and fed commercial rat chow MF (Oriental Yeast, Tokyo, Japan).  The 
animals were kept in individual cages with raised mesh bottoms to prevent coprophagy, and they 
were deprived of food but allowed free access to tap water for 18 h before the experiments.  Animal 
experiments were performed in compliance with the “Guiding Principles for the Care and Use of 
Laboratory Animals” approved by the Japanese Pharmacological Society and the guidelines 
approved by the Ethical Committee on Animal Care and Animal Experimentation of Josai 
International University (#52).  The number of animals used was kept to the minimum necessary for 
a meaningful interpretation of the data.
Experimental procedures
The animals were anesthetized with urethane (1.25 g/kg, i.p.).  The stomach was exposed through a 
midline incision, delivered onto the abdominal surface by gentle traction on the spleen, and the 
pylorus was ligated.  A two-part lucite chamber was used for maintaining ex vivo conditions of the 
gastric mucosa.  One part is a lucite base and the other is a plastic rim, which has two holes on the 
side wall.  The two holes are cannulated for perfusing the mucosa with saline (NaCl, 154 mmol/L at 
37°C) at a flow rate of 1 mL/min.  The lucite base was lowered over the animal, and the stomach 
was drawn though the center hole with the forceps applied only to the forestomach.  Then, the 
stomach was opened along the greater curvature from the middle part of the forestomach to the area 
where the epiploic artery terminates, and the edges were expanded by gently stretching the 
glandular mucosa.  The plastic rim was then applied and pressed down on the mucosa.  Under these 
conditions, only the glandular mucosa area, which consists mostly of the corpus region, was 
exposed.  The chamber was set at the level of the abdominal wall so that the external wall of the 
stomach remained inside the abdominal cavity.  The body temperature was maintained at a 
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temperature similar to that of the rectum at around 37°C by using an incandescent lamp [29].  
Gastric mucosal blood flow (GMBF) was measured using laser-Doppler flowmetry (Model 
ALF-21N; Advance, Tokyo, Japan) and a touching probe (diameter, 1 mm) on the surface of the 
corpus mucosa.  After the GMBF was well-stabilized, the perfusion was discontinued, the luminal 
solution was removed, and then the mucosa was exposed to 2 mL of DKT for 10 min or 30 min.  
After the application of DKT, the mucosa was rinsed with saline, another 2 mL of saline instilled, 
and the perfusion resumed.  Changes in the GMBF were continuously monitored and recorded for 
2-h test periods by using a PowerLab system (Model ML845; AD Instruments, Bella Vista, NSW, 
Australia).  A TRPV1 antagonist N-(4-t-butylphenyl)-4-(3-chlopyridin-2-yl) 
tetrahydropyrazine-1(2H)-carboxamide (BCTC) (0.8 mmol/L, intragastric [i.g.])?????
?????????????for 50 min, starting at 40 min before the DKT application [30,31].  Either a 
nonselective NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 10 mg/kg, i.v.) or a nNOS-
selective inhibitor NPLA (0.2 mg/kg, i.v.) was administered 20 min before exposing the stomach to 
2 mL of DKT for 10 min.  In some animals treated with L-NAME, L-arginine (300 mg/kg, i.v.) was 
administered twice 40 min and 60 min before the application of DKT.
Preparations and drugs used
Capsaicin, CMC, and urethane (ethyl carbamate) were obtained from Wako Pure Chemical 
Industries (Osaka, Japan).  L-arginine and L-NAME were from Sigma–Aldrich (St. Louis, MO, 
USA).  NPLA was from Tocris Cookson (Ellisville, MO, USA).  BCTC was purchased from 
BIOMOL (Plymouth Meeting, PA, USA).  BCTC was suspended in 10% 2-hydroxypropyl-β-
cycloxydextrin (Enzo Life Science, Farmingdale, NY, USA) and distilled water for i.g. application.  
DKT extract (Tsumura & Co., Tokyo, Japan, lot No. 2100100010) and maltose syrup powder 
(Tsumura & Co. Lot No. 3020168) were used.  DKT extract was obtained in the form of a spray-
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dried powder.  The extract solution was separated from the non-soluble waste and concentrated by 
removing water under reduced pressure.  DKT extract powder is manufactured as an aqueous 
extract that contains processed ginger, ginseng, and zanthoxylum fruit in the ratio of 5:3:2.  DKT is 
prepared by mixing DKT extract powder and maltose syrup powder at the ratio of 1:8.  DKT extract 
was suspended in distilled water for i.g. application.  Although the doses of TJ-100 in the present 
study (1440 mg/kg) are higher than the clinical doses used in humans, previous studies in animals 
have shown that the relevant pharmacological effects occur only in the experimental doses.  Other 
drugs were dissolved in saline with no organic solvent or detergent.  Each drug was prepared 
immediately before use and was administered at a volume of 0.5 mL/100 g of body weight in the 
case of i.p. and s.c. administration or at a volume of 0.1 mL/100 g of body weight in the case of i.v. 
administration.  Control animals received the vehicle alone.
Statistics
The data are presented as the mean ± standard error of mean (S.E.M.) of 4–7 rats per group.  The 
statistical significance of differences between two groups was assessed using Student’s t-test.  
Multiple comparisons against a single control group were made using one-way analysis of variance 
(ANOVA) with Bonferroni correction.  The level of significance was set at 0.05. Sigma Stat 3.1 
software (Jandel Scientific Software, San Rafael, CA, USA) procedure was applied for statistical 
analysis.
Results
Effects of intragastric DKT on GMBF in the stomach of anesthetized rats ex vivo
Intragastric administration of DKT (360, 720, 1440 mg/mL) induced gastric hyperemic responses in 
a concentration-dependent manner; a significant effect was observed at concentrations greater than 
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360 mg/mL (Fig. 10A).  GMBF remained high despite removal of DKT (over 720 mg/mL) from the 
chamber.  The maximal responses of GMBF to DKT (360, 720, 1440 mg/mL) during intragastric 
application for 10 min were 128.9 ± 6.2%, 136.0 ± 10.4%, and 162.9 ± 8.5% (Fig. 10B).  Mucosal 
application of the vehicle (distilled water) did not increase the GMBF (Fig. 10A, B).  Interestingly, 
the maximum GMBF after administration of 1440 mg/mL of DKT was similar to that observed after 
administration of 0.3 mg/mL of capsaicin to the rat stomach (Fig. 11A).  The gastric hyperemic 0
response to the 1st application of capsaicin decreased to the baseline after removal of capsaicin from 
the chamber.  The response to the 2nd application of capsaicin was about one-third of that to the 1st 
application.  On the other hand, the response to the 2nd application of DKT was almost as strong as 
that to the 1st application (Fig. 11B).  The above finding may be because, the GMBF reached its 0
maximum value after administration of 1440 mg/mL of DKT; thus, this concentration was used in 
the subsequent experiments to examine the effects of various agents on the GMBF in response to 
DKT.
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Fig. 11   Effect of mucosal application of either capsaicin or daikenchuto (DKT) on gastric mucosal 
blood flow (GMBF) in the stomach of anesthetized rats?ex vivo.  Figure A shows the time course of 
GMBF response to capsaicin (0.3 mg/mL) and DKT (1440 mg/mL) in anesthetized rats.  The stomach 
was perfused with saline, and capsaicin was topically applied to the mucosa for 10 min from time 0.  
The data are expressed as a % increase in baseline values and represent the mean ± standard error of 
mean (S.E.M.) of values obtained every 2 or 10 min from 6 to 7 rats.  Statistically significant difference 
at P < 0.05; * indicates from the group treated with capsaicin (0.3 mg/mL).  Figure B shows the effect of 
repeated application of capsaicin and DKT on the peak responses of GMBF (% increase from baseline 
values) in each group, and values are the mean ± S.E.M. of 6–7 rats.  * indicates statistically significant 
difference at P < 0.05 compared to the group treated one application.
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Effect of BCTC, a TRPV1 antagonist, on GMBF in response to DKT in the stomach of 
anesthetized rats ex vivo
The increase in GMBF in response to DKT (1440 mg/mL) was almost abolished in the animals 
when the mucosa was exposed to a TRPV1 antagonist BCTC (0.8 mmol/L) (Fig. 12).  The 
maximum response of GMBF induced by 1440 mg/mL DKT in the presence of BCTC was 122.5 ± 
10.1% throughout the experiment.  These findings suggested that intragastric DKT produced a 
significant increase in GMBF via activation of TRPV1, which is expressed in capsaicin-sensitive 
sensory nerves in anesthetized rats.
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Effect of NPLA, a selective nNOS inhibitor, on GMBF in response to DKT in the stomach of 
anesthetized rats ex vivo
The roles of different isoforms of NOS in gastric hyperemia induced by DKT were investigated by 
using the selective nNOS inhibitor NPLA.  The increase in GMBF in response to DKT (1440 mg/
mL) administration was not decreased by administration of 0.2 mg/kg NPLA.  The maximum 
GMBF during DKT application in animals treated with NPLA (0.2 mg/kg) was 147.7 ± 26.6% (Fig. 
14).
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Discussion
In this study, we found that mucosal application of DKT increased the GMBF in the stomach of 
rats, and this effect was partly blocked by a TRPV1 antagonist BCTC.  These findings suggest that 
this effect is mainly mediated by capsaicin-sensitive sensory nerves expressing TRPV1.  
NO is a well-known vasodilator that increases the GMBF, and this gastric mediator is important in 
the modulation of gastric mucosal integrity through interaction with sensory nerves.  Similar to the 
capsaicin-induced increase in the GMBF, the responses to DKT were also partly inhibited by a non-
selective NOS inhibitor L-NAME, which indicated a partial involvement of NO in those hyperemic 
responses.  The gastric hyperemia in response to DKT can be attributed to both NO-dependent and 
NO-independent hyperemia during capsaicin application in anesthetized rats.  Adrenomedullin and 
CGRP contribute to hyperemic responses to DKT in the small intestine of rats [11].  Gastric 
mucosal hyperemia in response to DKT may be attributable not only to NO but also to other gastric 
mediators, including adrenomedullin and CGRP.  On the other hand, NPLA, an inhibitor of nNOS, 
did not decrease the maximal GMBF response during the application of DKT.  The result suggests 
that nNOS/NO does not play an important role in the gastric hyperemia during the luminal 
application of DKT.  Further, eNOS is expressed mostly in the vasculature throughout the gastric 
mucosa in rats.  It is speculated that eNOS/NO may play an important role in the increased GMBF 
response to DKT.
Further studies are required to elucidate these unknown vasorelaxant mediators to clarify the 
mechanism underlying the increased GMBF induced by DKT.  Kampo medicines are used for 
various diseases in Japan.  DKT is one of the most frequently used Kampo medicine clinically 
effective for a cold sensation and dysmotility in the abdomen.  Although previous studies have 
shown the effect of DKT in improving these symptoms [42,43], our results indicate that DKT 
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stimulates TRPV1 on sensory nerves to induce the gastric circulation through NO release from 
TRPV1-expressing nerve fibers.  
Summary
I performed pharmacological studies and observed that DKT increases the GMBF through the 
activation of TRPV1.  TRPV1 stimulation by DKT in turn induced the release of NO derived from 
an NOS isozyme other than nNOS.  
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Concluding Remarks
I studied whether capsaicin and DKT increase the gastric mucosal blood flow through activation of 
TRPV1.
Part 1 Effects of the TRPV1 agonist capsaicin on gastric mucosal blood flow in rats
Mucosal application of capsaicin increased the GMBF by releasing NO derived from nNOS after 
stimulation of capsaicin-sensitive sensory nerves.  We showed the contribution of nNOS-derived 
NO in gastric hyperemic responses to the activation of TRPV1 by capsaicin not only using 
pharmacological tools but also using immunohistological techniques.
Part 2 Effects of DKT on gastric mucosal blood flow in rats
Pharmacological studies showed that DKT increases the GMBF through the activation of TRPV1.  
TRPV1 stimulation by DKT in turn induced the release of NO derived from an NOS isozyme other 
than nNOS.  
Conclusion
Capsaicin increases the GMBF in rats by stimulating the TRPV1 on sensory nerves and nNOS/NO.  
DKT increased the GMBF in rats by stimulating the TRPV1 on sensory nerves.  
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